NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US) Immunization Safety Review Committee. Immunization Safety Review: Vaccines and Autism. Washington (DC): National Academies Press (US); 2004.

Cover of Immunization Safety Review: Vaccines and Autism

Immunization Safety Review: Vaccines and Autism.

Show details

DChronology of Important Events Regarding Vaccine Safety

YearVaccine LicensureLegislation and/or Policy StatementsIOM Reports on Vaccine Safety
1955Inactivated poliomyelitis vaccine (IPV) available
1963Oral poliomyelitis vaccine (OPV) available, replaces IPV Measles vaccine available
Measles vaccine available
1967Mumps vaccine available
1969Rubella vaccine available
1971Measles-Mumps-Rubella (MMR) vaccine available
1977Mumps vaccination recommendedEvaluation of Poliomyelitis Vaccines
1979Current formulation of rubella vaccine available, replaces earlier versions
1982Plasma-derived hepatitis B vaccine available
1985Hib vaccine licensed for children >15 months
1986Congress passes P.L. 99-660, the National Childhood Vaccine Injury Act (introduced in 1984) calls for:
  • est. of NVPO
  • est. of NVAC
  • est. of VICP
  • est. of ACCV
IOM review of (1) pertussis and rubella, (2) routine child vaccines
1988Evaluation of Poliomyelitis Vaccine Policy Options
1990Two Hib conjugate vaccines licensed for use beginning at 2 months
1991Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in ACEL-IMUNEHepatitis B recommended by ACIP for addition to childhood immunization scheduleAdverse Effects of Pertussis and Rubella Vaccines
ACIP recommends Hib be added to childhood immunization schedule
1992Acellular pertussis component licensed for the 4th and 5th doses of the 5-part DTP series in TripediaHepatitis B vaccine: Added universal vaccination for all infants, high-risk adolescents (e.g., IV drug users, persons with multiple sex partners)
1993Combined DTP and Hib vaccine (Tetramune) licensed
1994Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality
DPT and Chronic Nervous System Dysfunction: A New Analysis
1995Varicella virus vaccine available (Varivax)
1996DTaP vaccine licensed for first three doses given in infancy (Tripedia and ACEL-IMUNE were previously licensed for only the 4th and 5th doses).ACIP recommends using IPV for the first 2 polio vaccinations, followed by OPV for remaining doses. Intended to be a transitional schedule for 3–5 years until an all-IPV series is availableOptions for Poliomyelitis Vaccinations in the United States: Workshop Summary
ACIP recommends children 12 months to 12 years receive Varicella vaccine
1997Additional DTaP vaccine (Infanrix) licensed for first 4 doses of 5-part seriesACIP recommends DTaP in place of DTPVaccine Safety Forum: Summary of Two Workshops
Risk Communication and Vaccination: Workshop Summary
1998Additional DTaP vaccine (Certiva) licensed for first 4 doses of 5-part seriesACIP updates MMR recommendation, encouraging use of the combined MMR vaccine
1999ACIP updates varicella vaccine recommendation, requiring immunity for child care and school entry
ACIP recommends an all-IPV schedule to begin January 2000 to prevent cases of vaccine-associated paralytic polio
AAP and PHS recommend removal of thimerosal from vaccines Also recommended postponement of hepatitis B vaccine from birth to 2-6 months for infants of hepatitis B surface antigen-negative mothers
Additional supply of thimerosal-free hepatitis B vaccine made availableMMWR notifies readers of the availability of a thimerosal-free hepatitis B vaccine, enabling the resumption of the birth dose
2000Pneumococcal vaccine for infants and young children licensed (Prevnar)ACIP recommends pneumococcal vaccination for all children 2-23 months, and at-risk children 24-59 months (e.g., immunocompromised)
2001October: ACIP drafts statement expressing a preference for use of thimerosal-free DTaP, Hib, and Hep B vaccines by March 2002Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism
Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders
2002Immunization Safety Review: Multiple Immunizations and Immune Dysfunction
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders
Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer
2003Live attenuated intranasal influenza vaccine approved for use in the United States in healthy individuals aged 5-49 years old (FluMist)ACIP recommends that children 6 to 23 months of age be vaccinated annually against influenza beginning in the 2004-2005 influenza seasonImmunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders
Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer
Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy
2004Immunization Safety Review: Influenza Vaccines and Neurological Complications
Copyright © 2004, National Academy of Sciences.
Bookshelf ID: NBK25351

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...